
SilverScript is owned by CVS Health Corporation (NYSE: CVS) and marketed under its Aetna Medicare brand. Launched in 2006 when Medicare Part D began, SilverScript Insurance Company underwrites standalone prescription drug plans (PDPs) that pair with Original Medicare. For 2026, SilverScript offers plans such as SilverScript Choice across most states, with premiums varying by region, a deductible up to the $615 federal maximum, and access to more than 63,000 network pharmacies. SilverScript is frequently misattributed to Centene; the brand has never been owned by Centene.
Parent Company
Founded
2006
Status
Publicly Traded
| Brand | Parent Company | Ownership Type |
|---|---|---|
| SilverScript | CVS Health Corporation | Wholly owned |
CVS Caremark launched SilverScript in 2006, the first year of Medicare Part D, as its flagship standalone prescription drug plan brand. The brand grew quickly, becoming the largest or second-largest standalone PDP issuer in the country and accumulating millions of members across nearly every state.
In 2018, when CVS acquired Aetna, the Department of Justice required Aetna to divest its standalone Medicare Part D business as a condition of approval because the combination would have concentrated the PDP market. Aetna's PDP members and contracts were sold to WellCare, completing in December 2019; CVS retained the SilverScript brand itself. From 2020 onward, CVS marketed SilverScript plans under the Aetna Medicare name, with benefit documents listing the insurer as "SilverScript Insurance Company (Aetna Medicare)."
This divestiture is the source of frequent confusion: the Aetna PDP members that went to WellCare became part of Centene when Centene acquired WellCare in 2020, but the SilverScript brand and insurance entity remained with CVS Health.
For plan year 2026, SilverScript offers plans including SilverScript Choice in most states. Premiums vary by region (ranging from roughly $22 to $98 per month in 2026 plan documents), with deductibles up to the $615 federal maximum. Following the Inflation Reduction Act, members' out-of-pocket Part D costs are capped at $2,100 in 2026, and SilverScript participates in the Medicare Prescription Payment Plan smoothing program.
What does CVS Health own?
CVS Health owns CVS Pharmacy (nearly 10,000 retail locations), CVS Caremark (pharmacy benefits management), Aetna (health insurance), MinuteClinic (retail health clinics), Oak Street Health (Medicare primary care), Omnicare (long-term care pharmacy), Navarro Discount Pharmacies, Longs Drugs, and Coram (infusion and home health services). These brands operate across three segments: Health Care Benefits, Health Services, and Pharmacy and Consumer Wellness.
Is CVS Health publicly traded?
Yes. CVS Health Corporation is publicly traded on the New York Stock Exchange under the ticker symbol CVS. The company is a component of the S&P 500 and is owned by institutional investors, mutual funds, and individual shareholders. There is no parent company or controlling shareholder.
Who founded CVS Health?
The original Consumer Value Store was founded in 1963 in Lowell, Massachusetts by Stanley Goldstein, Sidney Goldstein, and Ralph Hoagland. The company began as a health and beauty products retailer and added pharmacy departments in 1967. It was acquired by Melville Corporation in 1969 and spun off as an independent public company in 1996.
Where is CVS Health headquartered?
CVS Health is headquartered in Woonsocket, Rhode Island, USA. The company's corporate offices, including executive leadership, finance, and strategic operations, are based in Woonsocket, with additional operational offices across the United States.
How many brands does CVS Health own?
CVS Health owns approximately 9 brands across its three operating segments. The most prominent are CVS Pharmacy, CVS Caremark, Aetna, MinuteClinic, Oak Street Health, and Omnicare. The company also operates smaller regional brands including Navarro Discount Pharmacies and Longs Drugs.
Who owns CVS Health?
CVS Health is an independent publicly traded corporation with no parent company. The company is owned by institutional investors, mutual funds, and individual shareholders who hold its NYSE-listed common stock. Major institutional holders include Vanguard Group, BlackRock, and State Street Corporation. There is no founder control or dual-class share structure.
What were CVS Health's recent financial results?
For FY2025, CVS Health reported record revenue of $402.1 billion, up 7.8% year over year, and adjusted EPS of $6.75. In Q2 2026, revenue was $106.1 billion, up 7.3%, with adjusted EPS of $2.58, beating analyst estimates of $1.85. Net income nearly tripled to $3 billion. The company raised its 2026 guidance to at least $414 billion in revenue and adjusted EPS of $7.90 to $8.10.
Has CVS Health made major acquisitions recently?
The most recent major acquisitions were Oak Street Health for approximately $10.6 billion and Signify Health for approximately $8 billion, both in 2023. The largest acquisition in company history was Aetna for approximately $69 billion in 2018. CEO David Joyner has indicated the company has the capital and leadership bandwidth to pursue additional deals across its three business areas.
SilverScript operates under CVS Health's corporate responsibility framework, which includes drug pricing transparency initiatives, medication adherence programs, and pharmacy-access commitments for low-income seniors. The plans participate in Medicare's Low Income Subsidy (Extra Help) program for qualifying beneficiaries.
As a Medicare contractor, SilverScript is subject to CMS formulary, appeals, star-rating, and marketing-compliance rules, and to the Inflation Reduction Act's $2,100 out-of-pocket cap and Medicare Prescription Payment Plan requirements for 2026.
SilverScript plans carry CMS star ratings for Part D plans, which measure member experience, drug safety, and customer service. The brand's Aetna Medicare family has received mid-to-high CMS star ratings in recent plan years, and SilverScript remains one of the most-enrolled standalone Part D brands in the country.
2018 DOJ Divestiture Confusion: The CVS-Aetna merger forced Aetna's standalone Part D business to be divested to WellCare to resolve antitrust concerns. The divestiture created lasting market confusion, with many references incorrectly attributing SilverScript to Centene (which later acquired WellCare); the SilverScript brand never left CVS Health.
CMS Marketing Scrutiny: Medicare plan marketing is tightly regulated. SilverScript and other Part D plans have periodically been cited in CMS audits over marketing materials, call recordings, and broker conduct, standard across the industry.
Premium Volatility: SilverScript premiums have risen in several regions in recent years, drawing member complaints during annual enrollment as Part D plans restructure around the $2,100 out-of-pocket cap.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Centene | USA | 1985 | Mass market | United states | All-ages | |
| Centene | USA | 2014 | Market leader | United states | All-ages | |
| Cigna | USA | 1982 | Mass market | United states | All Genders | |
| Centene | USA | 1993 | Market leader | United states | All-ages | |
| Centene | USA | 1977 | Mass market | United states | All-ages | |
| Humana | USA | 1961 | Secondary line | United states | All-ages |
Healthcare PharmaceuticalsOwned by Centene Corporation
Centene Corporation's national Medicare Advantage and prescription drug plan brand, acquired from WellCare Health Plans for $17.3 billion in January 2020.
Healthcare PharmaceuticalsOwned by Centene Corporation
Centene Corporation's Affordable Care Act marketplace health insurance brand, launched in 2014 and serving 5.8 million members across 29 states as the largest individual-market issuer.
Healthcare PharmaceuticalsOwned by The Cigna Group
American health insurance brand providing medical coverage, health plans, and wellness services for individuals, families, and employers through The Cigna Group.
Healthcare PharmaceuticalsOwned by Centene Corporation
Centene Corporation's New York State health plan, founded in 1993 by the Catholic bishops of New York and acquired for $3.75 billion in July 2018, serving more than 2.4 million members.
Healthcare PharmaceuticalsOwned by Centene Corporation
Centene Corporation's California health plan brand, founded in 1977 and acquired for approximately $6.8 billion in 2016, serving about three million members through Medi-Cal, Medicare, marketplace, and commercial plans.
Healthcare PharmaceuticalsOwned by Humana Inc.
Humana's employer group insurance line providing medical, dental, vision, life, and disability coverage to businesses across the United States.
Market Positioning: SilverScript competes with 6 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by CVS Health Corporation, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by Walgreens Boots Alliance
Boots is the UK's leading pharmacy-led health and beauty retailer, founded in 1849, now operating as The Boots Group under Sycamore Partners since August 2025.
Boots is privately owned, unlike SilverScript which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Walgreens Boots Alliance
Duane Reade is a New York City drugstore chain owned by Walgreen Co. under Sycamore Partners, operating approximately 90 stores across the five boroughs.
Duane Reade is privately owned, unlike SilverScript which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Chempro Chemists
Australian online pharmacy operated by Chempro Chemists from Molendinar, Queensland. Offers prescription medications, health products, and wellness items through digital platforms and mail-order delivery.
Pharmacy Direct is privately owned, unlike SilverScript which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
Tirosint is privately owned, unlike SilverScript which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Walgreens Boots Alliance
Walgreens is the largest U.S. pharmacy retail brand, operating roughly 8,000 stores. It went private in August 2025 under Sycamore Partners as a standalone company.
Walgreens is privately owned, unlike SilverScript which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Amgen Inc.
Master biotechnology brand of Amgen Inc., the world's largest independent biotech, covering its full portfolio of biologic medicines.
Amgen operates independently without a large parent corporation.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.

Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.